Ourense

• Ursodeoxycolic acid for the prevention of relapsing complications after gallstone acute pancreatitis, a double-blind multicenter randomized- … Pending
  2024-518237-28-00 6 recurrence of acute biliary pancreatitis
• Moonlanding: A phase 2 study of pembrolizumab plus belzutifan, with or without lenvatinib, given before the main treatment for localized kid … Pending
  2024-519673-18-00 4 Patients with localized renal cell carcinoma
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tum … Pending
  2025-521209-42-00 6 advanced colorectal cancer with wild-type RAS and right primary tumour
• Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with adv … Pending
  2025-524048-36-00 5 Advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcin
• A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder. Pending
  2025-524488-18-00 4 Muscle-invasive Bladder Cancer
• Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending
  2025-524640-35-00 4 Ulcerative colitis (Inflammatory Bowel Disease)
• Immunosuppressant Discontinuation in Elderly patients with ulcerative colitis And long-term remission Recruiting
  2025-524675-23-00 6 2026-06-24 Ulcerative Colitis
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Recruiting
  2025-521038-27-00 5 2026-06-23 Immune system diseases
• Grass Immunotherapy for Rhinitis and Asthma (GIRA) Recruiting
  2025-521736-10-00 5 2026-06-23 Allergic rhinoconjunctivitis with or without controlled asthma
• A Worldwide Study Testing the New Drug Lisaftoclax for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma … Recruiting
  2024-514084-26-00 5 2025-08-22 Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphom
• Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma Recruiting
  2024-516233-12-00 3 2025-08-08 Advanced pancreatic adenocarcinoma
• Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Recruiting
  2022-501105-12-00 5 2024-07-15 Urothelial Carcinoma
• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che … Recruiting
  2022-502660-20-00 5 2024-01-23 Follicular lymphoma
• A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS … Recruiting
  2022-500479-29-00 10 2023-03-28 International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte
• Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery Recruiting
  2024-515830-34-00 5 2023-02-14 Congenital antithrombin deficiency
• Efficacy of the use of neoadjuvant with/without hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced colon cancer Recruiting
  2025-520471-29-00 5 2026-05-26 Locally advanced adenocarcinoma of the colon and upper rectum with mic
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma
• Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot re … Recruiting
  2024-515201-26-00 4 2025-12-09 Small cell lung cancer (SCLC)
• A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting
  2025-521242-26-00 4 2025-11-27 Moderately to Severely Active Ulcerative Colitis
• A Phase 2 Study of Momelotinib in Participants with low-risk myelodysplastic syndrome Recruiting
  2024-519928-24-00 4 2025-08-21 Myelodysplastic Syndrome
• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph … Recruiting
  2023-509630-19-00 5 2025-07-31 Esophageal Squamous Cell Carcinoma (ESCC)

Showing 1–24 of 70 trials